Wilson Marc 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jul 2, 2024
Insider Transaction Report
Form 4
Wilson Marc
CFO
Transactions
- Sale
Common Stock
2024-06-28$43.61/sh−32,129$1,401,146→ 111,092 total - Exercise/Conversion
Stock option (Right to Buy)
2024-06-28−32,129→ 19,056 totalExercise: $9.28Exp: 2028-05-24→ Common Stock (32,129 underlying) - Exercise/Conversion
Common Stock
2024-06-28$9.28/sh+32,129$298,157→ 143,221 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.61 per share. The range of sales prices on the transaction date was $43.28 to $44.13 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]Includes 462 shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F4]1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.